Annual Inflammasome Summit unites world renowned experts in inflammasome-targeted drug development and academia to share information and address knowledge gaps in this rapidly evolving field ZyVersa is well positioned in the emerging inflammasome space with a highly differentiated inflammasome ASC
Special meeting of Larkspur stockholders scheduled for December 8, 2022, to vote on the proposed business combination of Larkspur with ZyVersa ZyVersa is a clinical stage biopharmaceutical company with two licensed proprietary product platforms, a cholesterol efflux mediator targeting multiple
Mr. Glover will be joining four other life science executives in a General Session titled, CEO Panel: Learn from the experts ZyVersa is a clinical stage biopharmaceutical company with two licensed proprietary product platforms targeting renal and inflammatory diseases ZyVersa and Larkspur Health
Aggregate committed financing in support of the business combination now at $10.0 million ZyVersa and Larkspur entered into a definitive business combination agreement on July 20, 2022 ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates to address
Age-related chronic inflammation induced by activation of NLRP1 inflammasomes is implicated in development and progression of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases IC 100 research was conducted at the University of Miami Miller School of Medicine by acclaimed
BRIDGEWATER, N.J. and WESTON, Fla., Aug. 15, 2022 /PRNewswire/ -- Larkspur Health Acquisition Corp. (NASDAQ: LSPR or "Larkspur"), a blank-check special purpose acquisition company, and ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging
IC 100, a novel monoclonal antibody inflammasome ASC inhibitor, targets multiple types of inflammasomes to block initiation and perpetuation of damaging chronic inflammation IC 100 has broad tissue distribution, including CNS and peripheral tissues, is rapidly internalized by a variety of cell
Compelling evidence that chronic neuroinflammation induces neurodegeneration in Parkinson's disease (PD) Hypothesized that microglial inflammasome activation propagates chronic neuroinflammation in PD IC 100, a CNS-penetrating monoclonal ASC Inhibitor, targets multiple types of inflammasomes to
ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates to address significant unmet medical needs of patients with renal and inflammatory diseases Lead renal product candidate, phase 2a-ready VAR 200, mediates removal of excess intracellular lipids that
Video features researchers at the University of Miami Miller School of Medicine: Dr. Alessia Fornoni, Katz Professor of Medicine, Chief, Katz Family Division of Nephrology & Hypertension & Director of Peggy & Harold Katz Drug Discovery Center Dr. Sandra Merscher, Research Associate Professor, Katz
